Immunome, Inc. (IMNM)
Nasdaq: IMNM · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2009
Who owns Immunome, Inc.
As filed with the SECHolders of 5% or more
3
T. Rowe Price Investment Management, Inc. holds 17.4% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
13
report now, of 29 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · 14.5% in May 15, 2026
Fmr LLC
SCHEDULE 13G/A · filed Oct 7, 2025 · COMMON STOCK · 7.1% in Aug 6, 2025
Immunome Aggregator, LP
SCHEDULE 13D/A · filed Feb 4, 2025 · Common Stock, par value $0.0001 per share
Redmile Group, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.2% in Feb 17, 2026
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock · reported falling below 5%
Sirenia Capital Management LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in May 15, 2026
Enavate Sciences GP, LLC
SCHEDULE 13D/A · filed Dec 22, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 14, 2025 · Common Stock · reported falling below 5%, from 5.5% in Feb 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.9% in Feb 3, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.2% in Jul 29, 2025
What IMNM reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Ayala Purchase Agreement
A company bought · asset acquisition · owns, named in the 10-K filed Mar 3, 2026
Zentalis Purchase Agreement
A company bought · asset acquisition · owns, named in the 10-K filed Mar 3, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 28, 2024.
Insider tradesForm 4
28sales
11purchases
24sales on a scheduled plan
7people selling
$27.5Msold, in dollars
$2.3Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Barchas Isaac | director | 12 | $18.3M | 12 | 0 | $0 |
| Rosett Max | Chief Financial Officer | 3 | $2.5M | 3 | 0 | $0 |
| Horn Kinney | CHIEF BUSINESS OFFICER | 2 | $2.3M | 2 | 0 | $0 |
| Lechleider Robert | Chief Medical Officer | 5 | $2.3M | 5 | 0 | $0 |
| Wagenheim Philip | director | 2 | $1.3M | 0 | 0 | $0 |
| Higgins Jack | Chief Scientific Officer | 2 | $500,000 | 2 | 0 | $0 |
| Bienaime Jean Jacques | director | 2 | $200,000 | 0 | 6 | $400,000 |
| Siegall Clay B | President and CEO | 0 | $0 | 0 | 4 | $1.7M |
| Tsai Philip | Chief Technical Officer | 0 | $0 | 0 | 1 | $200,000 |